The target-controlled infusion (TCI) of propofol was initially implemented commercially using the Diprifusor control module (AstraZeneca PLC, London, UK), with a compartmental pharmacokinetic model based on that described by Gepts et al 1 , with some minor modifications to the volume of the central compartment (V 1 ) by Marsh et al 2 based on their pilot studies. Other TCI pumps using the Diprifusor system include the Graseby 3500 (Graseby Medical, Watford, UK), the Vial Medical Master (Fresenius Vial, Brezins, France) and the Alaris IVAC TIVA (Alaris Medical Systems, Basingstoke, UK). 'Open' TCI systems, which may offer a menu of parameterised pharmacokinetic models for a number of drugs and do not require the use of special pre-loaded syringes, include the Alaris Asena PK syringe pump and Base Primea from Fresenius Vial 3 . Diprifusor model-based systems scale linearly for body weight only, while the other model systems are based on the kinetics of Schnider et al 4 with adjustments for age and weight, expressed as lean body mass (LBM). The archetypal flexible research tool is Stanpump 5 which allows the use of existing models for many drugs as well as allowing an operator with a high level of involvement to supply an individual parameter set. Other similar research implementations include Rugloop (bvba Demed, Tremse, Belgium).
A principal source of error in existing compartmental models is that much of the data used to derive the model has been obtained from studies not designed to achieve concentrations close to those used in clinical anaesthesia. Often data has been obtained during constant rate infusions or during the period when drug levels fall after cessation of an infusion. Davidson et al 6 , for example, observed that the compartmental model used in the Diprifusor performed well some 90 seconds after the infusion pump had been turned off, but exhibited a large positive bias during the actual delivery of the drug. Schüttler and Ihmsen 7 pooled data from a number of sources and used population pharmacokinetic analysis to obtain a three-compartment model. They
SUMMARy
Nineteen adult patients of either gender received intravenous infusions of propofol, scaled to estimated lean body mass (LBM), for 150 minutes as part of a balanced anaesthetic. Arterial blood was assayed for whole blood propofol. The first subject received propofol at a fixed rate of 0.058 mg.min -1 .kg LBM -1 . Subsequent groups received variable rate infusions based on the ratio of the infusion rate to the propofol concentration at each sampling point in the previous group, multiplied by the target concentration. After groups of one, two, five and 11 subjects, the median weighted residual was 0.040 and median absolute weighted residual was 0.153. Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V 1 =0.102 (0.0155) l/kg LBM , V 2 =0.257 (0.079) l/kg LBM , k 10 =0.423 (0.069) /min, k 12 =0.222 (0.051) /min, k 21 =0.084 (0.02) /min and clearance=0.0418 (0.0023) l.min -1 .kg LBM -1 . The only significant covariate was LBM. Within infusion data improved prediction when compared with data derived in previous studies from random observations. observed that the inclusion of data obtained during long elimination periods was a major source of error. They also noted that the inclusion of data associated with bolus dosing led to over-estimation of V 1 . An evaluation of various predictive pharmacokinetic models has recently been published by Glen and Servin 8 comparing measured and simulated concentrations using a three-stage infusion protocol.
The present study is aimed at producing infusion profiles suitable for TCI. It aims at developing a simple table for infusion of any formulation of propofol. A table can be implemented in a standard syringe pump by manually adjusting the infusion rate over time. Tabular values can also be applied to a Stanpump-driven infusion pump in order to generate a series of stepped infusion rates. A further objective of this study is to generate a compartmental pharmacokinetic model suitable for continuous computation by programs such as Stanpump. This study describes refinements of a modelindependent approach previously used for deriving infusion rates for thiopentone and methohexitone 9 . The method used is aimed at deriving a simple series of short (stepped) infusion rates designed to achieve a target concentration of propofol in surgical patients for infusions of up to 150 minutes duration. Such concentration-time data can also be used to derive a compartmental pharmacokinetic model using population pharmacokinetic analysis. The resulting sets of data can then be of further use to confirm the effectiveness or otherwise of the non-parametric approach. If the non-parametric approach is as effective as the model-based approach, model-independent measurements such as clearance should be comparable between the two methods, as well as with published values. A variable rate infusion, derived during clinical anaesthesia, provides an environment where sources of betweensubject variability are minimised and potential sources of within-subject variability are maximised 10 .
MATERIALS AND METHODS
Following institutional approval and the obtaining of written informed consent, adult patients of either gender who were to undergo surgery under general anaesthesia were enrolled. Anaesthesia was induced with thiopentone, neuromuscular blocking agent, isoflurane and nitrous oxide, and surgery then commenced. After a variable period of at least 15 minutes and once conditions were stable, a propofol infusion was administered according to a predefined protocol (see below) and the volatile agent discontinued while continuing the use of nitrous oxide in order to provide analgesia.
Determination of a plasma drug efflux profile
Infusions of propofol were administered with dosage based on the LBM of each subject, estimated using the method of James 11 from gender, total body weight (TBW) (kg) and height (Ht) (cm), as follows:
LBM (males)=1.10 TBW-128 (TBW/Ht) 2 LBM (females)=1.07 TBW-148 (TBW/Ht) 2 The process used is presented in Figure 1 . The first subject was administered propofol by intravenous infusion at a fixed rate of 0.058 mg.min -1 .kg LBM -1 , using a conventional syringe pump (Terumo, Model STC-521). Blood samples were taken from a radial artery cannula placed for pressure monitoring at 1, 2, 3, 6, 8, 11, 16, 21, 31, 46, 61, 76, 91, 106, 121 and 151 minutes from the commencement of the infusion and assayed for blood propofol concentration by high pressure liquid chromatography by a standard method to create a table of measured concentrations (C m ).
The intravenous infusion site was considered the reference point for time and arterial plasma concentrations were corrected by minus one minute when calculating each value. This correction was made on the basis that the vein-to-artery transit time was unknown in each patient but would be too short if taken as zero and too long if taken as two minutes. The delivery rate (mg.min -1 .kg LBM -1 ) was divided by the time corrected arterial plasma concentration (mg/l). This calculation was successively applied to all concentration measurements during the study period in order to determine the plasma drug efflux (PDE) profile values (l.min -1 .kg LBM -1 ), corrected as described (also see Crankshaw et al 12 ) . The values of the PDE profile for the first subject were plotted as a function of time and a plasma drug efflux profile (Ep) at one-minute intervals was then generated by linear interpolation. These values were transferred to a programmable infusion device (see Crankshaw et al 12 ). An infusion was administered to a second group of two subjects with a target concentration (C TGT ) of 2 mg/l of propofol. The delivery rate (mg/ min) for each subject was produced by continuous multiplication of the successive values of Ep (read from the memory each minute) by C TGT (mg/l) and by the LBM (kg) of the particular subject.
Successive groups of subjects were infused using the same process, with the infusion rate-time profile calculated from the previous group of subjects. The size of each group was chosen to increase progressively during the iterative process. The decision to accept an infusion profile as optimal and stop the iterative process was made by comparing values of C m at each sampling point using Wilcoxon's matched pairs test (CSS-Statsoft) to identify bias from C TGT . A non-significant result (P >0.05) was used to terminate the iterative process. Bias and inaccuracy were determined for each group of patients from all the C m and C TGT pairs for that group. The goodness of fit of measured values (C m ) relative to the prediction (C TGT ) was expressed in terms of weighted residuals (WR), where:
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WR=(C m -C TGT )/C TGT (1) Then, the success of the infusion regimen in each group of patients is described by the systematic failure to achieve C TGT (bias), expressed as median weighted residuals (MDWR), where:
MDWR=median {WR 1 , WR 2 , WR 3 ,… WR n } (2) and by the sum of the absolute deviations of C m from C TGT (inaccuracy), expressed as the median absolute value of the weighted residuals (MDAWR), where:
MDAWR=median {|WR 1 |, |WR 2 |, |WR 3 |,… |WR n |}.
Determination of a compartmental pharmacokinetic model
Data obtained from the final iteration of the process for generating the PDE profile were used to derive a population pharmacokinetic model using NONMEM 13 . The object was to determine the most suitable model and to identify the more influential covariates such as age, height, total body weight, lean body mass, gender and target concentration which affected the model. The analysis was facilitated by use of generalised additive models to identify the influential covariates 14, 15 , an approach which made use of the data analysis programs S-PLUS and Xpose3 16 . More important covariate effects on each of the model parameters were sought using the Akaike Information Criterion, which allows choosing between models where increase in parameter count might lead to spurious improvement of fit 17 . Separate structural models, incorporating these covariates, were then tested with NONMEM using its first order conditional estimation method with interaction between intra-and inter-individual variance and a proportional and additive error model. Two-and three-compartment models were fitted to the data using the NONMEM objective function as the primary criterion of best fit.
RESULTS
A total of 19 patients were studied. The results of testing for departure from C TGT are shown in Table 1 . In the first patient, who received a fixed rate infusion of 0.058 mg.min -1 .kg LBM -1 for 150 minutes, there is obvious departure from C TGT . In the second group of two patients, with a C TGT of 2.5 mg/l, plasma concentrations (C m2 ) are shown in Figure 1 . C m2 data were not evenly distributed around the C TGT (Wilcoxon P >0.05) with the MDWR (0.150) and MDAWR (0.290). The Wilcoxon test (Table 1 ) returned a non-significant difference from C TGT in Group 4, with a total of 11 subjects, and a very small bias. Table 2 shows the physical characteristics of the patients in Group 4 including the percentage fat. The values of Ep3 used to generate the infusion rates for this final group are shown in Table 3 , together with the profile Ep4, generated from Ep3 and C m4 .
The two-compartment pharmacokinetic model, with parameters derived by population pharmacokinetic analysis using NONMEM, is illustrated in Figure 1 . The parameters of the model, with standard errors, are V 1 =0.102 (0.0155) l/kg LBM , V 2 =0.257 (0.079) l/kg LBM , k 10 =0.423 (0.069) /min, k 12 =0.222 (0.051) /min, k 21 =0.084 (0.02) /min and clearance= 0.0418 (0.0023) l.min -1 .kg LBM -1 . The addition of covariates other than LBM did not improve the performance of the model.
Comparison of the PDE method with the compartmental model was made by substituting the population predicted value C pred for C TGT so that:
The comparative values for bias and inaccuracy are given in Table 1 .
DISCUSSION
The PDE approach proved a highly efficient method for deriving pharmacokinetic data suitable for generating TCI in a surgical population of diverse morphology and age. Only eight subjects were used to create the infusion profile tested in the final subject group. In this final group of 11 subjects, an MDWR (bias) of 0.040 and an MDAWR (precision) of 0.153 was observed. The bias was similar to the 0.034 observed by Schüttler and Ihmsen in pooled data 7 but the precision was twice that seen by these authors. We would attribute this to dosing based on lean body mass and in part to the use of an adult study group.
Simulation of the performance of our twocompartment model resulted in a bias of -0.008, which was extremely small and similar to the -0.004 obtained for a three-compartment model by Schüttler and Ihmsen 7 . The precision of our model of 0.140 was better than the 0.255 they obtained, suggesting again the value of dosing based on lean body mass, although there may be other factors which might contribute to these differences. The results indicate that it is not necessary to account for age provided the infusion is scaled to lean body mass. The results serve to emphasise the importance of dosing on the basis of a measure such as lean body mass in adult human pharmacokinetic studies which corrects for the wide range of body morphology.
While the results are based on a very limited data set, they demonstrate the power of combining the methods of PDE and population pharmacokinetic analysis to derive pharmacokinetic models. The targeted PDE approach, followed by population pharmacokinetic analysis with NONMEM, has advantages of easy application to defined groups and easy replication as part of the validation process, prior to wider introduction of the models into clinical practice. The limited patient data needed to create the PDE infusion rate-time profile and the The correction of concentration data by minus one minute has a number of advantages. The inclusion of a correction for transit time should more accurately reflect the mixed venous concentration of drug at the point of injection than the arterial blood sampled at the exact time of the injection. Further, it results in data at zero time for subsequent infusions where extrapolation would otherwise be required. Any loss of propofol in the pulmonary circulation would of course be accounted for in the calculation of Ep when determining infusion requirements.
It was apparent in successive profiles, Ep1 through Ep4 (Figure 1) , that there was a recurring shape, with high initial infusion requirements, followed by a somewhat lower infusion requirement towards the end of the first hour and then by a higher requirement in the second hour. The function has the appearance of a damped oscillation. Transient cardiovascular effects of propofol, followed by physiological compensation, are a possible explanation and clearly illustrate the particular robustness of the efflux technique. The method uses data derived entirely under clinical conditions and in the midst of the physiological changes that propofol may cause when used at clinical concentrations for anaesthesia. Consistent effects of drug-related physiological changes over time on the pharmacokinetics of a drug will be allowed for by the iterative and model-independent nature of the efflux process and be reflected in the final efflux profile, regardless of their exact physiological origin.
The shape of the infusion profile required to produce a constant propofol concentration in clinical anaesthesia could not be created by solving the compartmental pharmacokinetic model in the conventional way, as it is assumed that the model parameters do not change in time. NONMEM includes the ability to incorporate time-varying covariates, but we were unable to demonstrate an improved fit by taking this phenomenon into account. Further pharmacokinetic analysis using time-varying covariates and larger data sets would be required to investigate these observations (Appendix 1).
The choice of a C TGT of 3 mg/l of propofol, in the presence of nitrous oxide for the final iteration of this study, was based on prior experience in providing surgical anaesthesia with the propofol/ nitrous oxide combination. This value of C TGT provided satisfactory anaesthesia in all subjects studied and titration was not required. The lack of any need to adjust C TGT up or down can be explained by the concurrent use of nitrous oxide and neuromuscular blocking agents. Satisfactory clinical conditions including cardiovascular stability and the absence of any recall of intraoperative events by the subjects indicated that the infusions achieved a satisfactory result in each case.
The study resulted in two sets of data, each suitable for programming TCI infusion pumps to administer propofol to adults as part of a balanced anaesthetic technique. The first set of data consists of the rate time pairs shown in Table 3 . Assuming linearity within the clinical range, as is done with current TCI methods, the PDE values are most suitable for achieving a nominated C TGT for a period of 150 minutes. PDE data are not suitable for predicting infusion requirements when C TGT is stepped up and, equally, are not suitable for predicting how long an infusion should be stopped in order to achieve a lower C TGT . However, anaesthetists would be familiar with the concepts of 'over pressure' and 'decay in concentration' when they administer volatile agents and could easily adapt these concepts to TCI.
The PDE data can be used to generate a variable rate propofol infusion (mg/min) with a programmable infusion pump by continuously multiplying the PDE value (l.min -1 .kg LBM -1 ) by the target concentration (mg/l) and the estimated LBM of the subject (kg). This was the method used in the present study. An alternative is manual adjustment of the infusion according to the table of rate against time for various weights and target concentrations. The number of steps is considerably less ( Table 4 ) than those we have published previously for thiopentone and methohexitone 18 , due to the rapid approach of the propofol infusion profile to a constant rate.
The second set of data, the compartmental pharmacokinetic model shown in Figure 1 , is suitable for titrating to any target concentration. The computations required to achieve practical clinical infusions are more complex than those for PDE, involving continuous solution of equations. This process can be performed using the Stanpump or similar algorithms (see Glass et al 19 ) , however the regulatory process has limited the commercial implementation of this approach 20 . Usually, predictive models (see references 6, 7, 21 ) make the assumption that the compartmental pharmacokinetic model describes the distributive properties of propofol throughout the clinical range and assume accuracy for infinite time. The present model which has been derived from data, obtained during infusions of 150 minutes duration, could equally well be used for longer periods, as is done with other models.
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The non-parametric PDA profile can not be used to predict post infusion drug concentrations. On the other hand, compartmental pharmacokinetic models are commonly used to do this. The model used in the Diprifusor has, in fact, been reported to predict post-infusion drug concentrations very well in contrast to its performance when the infusion is running 6 and likely reflects the diminishing circulatory effects of propofol as concentration decreases below anaesthetic concentrations. It may be that separate models are required to describe the pharmacokinetics of propofol in the post-infusion period (see Davidson et al 6 and also Appendix 2 to Barr et al 21 ) . Our experience with clinical infusions, in contrast to the experience of others 19 , is that titration is the exception rather than the norm, even in the absence of neuromuscular blockade. The performance of a TCI device should depend mainly on its within-infusion performance.
Finally, the value of Ep of 0.041 to 0.045 l.min -1 .kg LBM -1 for the period 45 to 150 minutes of the PDE profile (Table 3 ) corresponded closely to the value for clearance of 0.0418 l.min -1 . kg LBM -1 obtained for the two-compartment model. Others 2,7 report clearances in the range of 0.018 to 0.027 l.min -1 .kg -1 in adults which are similar if a correction is made for the use of LBM.
In conclusion, we present a method of generating pharmacokinetic data suitable for programming target-controlled infusion pumps by generating infusion rate tables. The method of deriving the data converges rapidly on the required outcome using simple statistical tests with a small number of subjects. The convergence is to a specific target concentration, but the method can be easily applied to different target concentrations and be used to determine the linearity or otherwise of the infusion pharmacokinetics of any drug. At the same time data can be collected for traditional pharmacokinetic analysis.
APPENDIX 1
According to current concepts, a constant concentration can be established in the central compartment of a mamillary model with a bolus dose of C pd .v 1 and a time-varying infusion, so that:
where efflux (t) is the rate of drug loss, C pd is the target drug concentration, k ij are intercompartmental rate constants, v 1 is the volume of the central compartment, and N is the number of compartments in the model.
Over time, the second term in the brackets approaches zero and the input rate becomes constant. At all times the drug input is equal to the efflux of drug from the central compartment by whatever pathway. This input function, derived from the parameters of a compartmental model, is a combination of exponentially decreasing curves approaching a plateau.
The efflux function we describe in this paper (Ep3) differs somewhat from any function that could be derived by applying Equation A1. Figure 2A shows the output of this model (dotted line) along with Ep3 (solid line). The smooth exponential curve derived from the parametric model contrasts with Ep3 which shows a relatively prolonged dip which has the form of an exponentially damped oscillation (broken line). We fitted a function to the Ep3 data using nonlinear least squares curve fitting with the Mathcad ® function Genfit by adding a third term to Equation A1 to produce the following: F (t)= θ 0 +θ 1 e -θ2 t +θ 3 cos (θ 4 t+θ 5 ) e -θ6t (A2) where the θ i are parameters to be derived by fitting the function to the input rates of Ep3. The first two terms are of the form used in Equation A1 with the third term conferring an exponentially decaying oscillation. The period of this oscillation is 2.π/θ 4 , approximately 120 minutes and is shown in Figure 2A as a broken line. The cause of the oscillation, which was apparent in all of the study groups, is not clear and may be due in part to the effects of propofol on its own pharmacokinetics. APPENDIX 2 Table 4 provides propofol bolus doses and infusion rates predicted to achieve and maintain an arterial concentration of 3.0 mg/l. Dosage is based on lean body mass of males and females. The steps, shown as a broken line in Figure 2B are a simplification of Ep3, suitable for manual entry into an infusion pump. Titration while following Table 4 can be achieved by moving left or right to another column, during the infusion. This table makes no allowance for equilibration with the effect site (see Glass 19 ). In practice, an increase in the bolus dose will ensure an appropriate clinical response.
(A1)
figure 2a: Infusion rates predicted to maintain a constant plasma concentration of 1 µg/ml of propofol during a 150 minute infusion.
The solid line represents the infusion rate profile determined by iterative fitting (Ep3), normalised to unit LBM. The dotted line represents the prediction from the compartmental pharmacokinetic model, using function A1. The broken line is the prediction from the compartmental pharmacokinetic model, modified with a damped oscillation shown in Equation A2. figure 2B : Plasma drug efflux profile for iteration Ep3 and a simplified profile (broken line) suitable for programmed delivery with a simple infusion pump as shown in Table 4 . Ep=efflux profile, LBM=lean body mass.
taBle 4 Bolus doses (ml) and infusion rates (ml/h) of propofol, for a syringe
concentration of 10 mg/ml, predicted to achieve an arterial blood concentration of 3.0 mg/l. Dosage is scaled to estimated LBM (see Methods). The profile is shown as the broken line in Figure 2B . 
